We recently published a list of 11 Best 3D Printing and Additive Manufacturing Stocks to Buy. In this article, we are going ...

Citi analyst Geoff Meacham raised the firm’s price target on PTC Therapeutics (PTCT) to $50 from $46 and keeps a Sell rating on the shares ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics ...

Some grimace, others look puzzled. "PTC perception is arguably one of the most studied human traits," says Sun-Wei Guo, a professor of pediatrics and biostatistics at the Medical College of Wisconsin ...

PTC expects FDA approval for sepiapterin by July 29, 2025, with regulatory decisions in Europe and Japan later in the year. Feel unsure about the market’s next move? Copy trade alerts from Matt ...

PTC Therapeutics (PTCT) shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 ...

PTC Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $213.17 million for the quarter ended December 2024, missing the Zacks Consensus ...

WARREN, N.J., Feb. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application ...

PTC's ability to globally commercialize products ... access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific ...